Please assess the completion status of the following clinical trial:

Trial Title: Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol~* Children, male or female, aged between 6 and 35 months at the time of first study vaccination.~* Written informed consent obtained from the parent(s) or LAR(s) of the subject.~* Healthy children, as established by medical history and clinical examination when entering the study.~* Parent/LAR with access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period.~* Clinically or virologically confirmed influenza infection within six months preceding the study start.~* Planned administration of any vaccine 30 days prior and 30 days after any study vaccine administration.~* Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to enrolment in this study or planned administration during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination~* Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.~* History of hypersensitivity to vaccines.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines~* History of any neurological disorders or seizures.~* Acute disease and/or fever at the time of enrolment~* Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned during the study.~* Any condition which, in the opinion of the investigator, renders the subject unfit for participation in the study.~* Child in Care.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- GSK 2340272A F1 Group (Type: EXPERIMENTAL): Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 1 (F1) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (\<) 12 months at study entry.
- GSK 2340272A F2 Group (Type: EXPERIMENTAL): Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 2 (F2) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (\<) 12 months at study entry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete